{"name":"SciClone Pharmaceuticals","slug":"sciclone-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"SciClone Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies in oncology and immunology. The company has a diverse pipeline with several drugs in various stages of clinical development, including thymalfasin (thymosin alpha 1) and SCV-07.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":160096000,"revenueGrowth":1.8,"grossMargin":0,"rdSpend":0,"netIncome":30729000,"cash":241898000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2016"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"placebo + PEGinterferon alfa-2a","genericName":"placebo + PEGinterferon alfa-2a","slug":"placebo-peginterferon-alfa-2a","indication":"Chronic hepatitis C (in combination with ribavirin)","status":"phase_3"},{"name":"thymalfasin (thymosin alpha 1)","genericName":"thymalfasin (thymosin alpha 1)","slug":"thymalfasin-thymosin-alpha-1","indication":"Severe herpes simplex virus infections","status":"phase_3"}]}],"pipeline":[{"name":"placebo + PEGinterferon alfa-2a","genericName":"placebo + PEGinterferon alfa-2a","slug":"placebo-peginterferon-alfa-2a","phase":"phase_3","mechanism":"PEGinterferon alfa-2a is an immunomodulatory agent that enhances antiviral and anti-tumor immune responses by activating interferon signaling pathways.","indications":["Chronic hepatitis C (in combination with ribavirin)","Chronic hepatitis B"],"catalyst":""},{"name":"thymalfasin (thymosin alpha 1)","genericName":"thymalfasin (thymosin alpha 1)","slug":"thymalfasin-thymosin-alpha-1","phase":"phase_3","mechanism":"Thymalfasin (thymosin alpha 1) is a peptide that stimulates the immune system by activating T cells and natural killer cells.","indications":["Severe herpes simplex virus infections","Severe fungal infections"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPR0dzTG9uempFSUtaWEFTckI2Q1d6djR4dEhVYkFITVZEU0U2Y3JxRFJKZ3NfeHdCVVJ6SkplS3VHNjlhVllYVXltSUQ0bG1XWU54dHlLY2NOVm5HR05tekFVX25fT3REOE43X1lGYWZPQTNtS1hkejV6cVpGOFlHRXVrVnBveXpoQTByOXUyMkYzdnYwR09zcHNZRC16ajBrYUtWSkV6NHNQUklTend0VzZlM0lWMloteXkwUXRiMA?oc=5","date":"2025-09-09","type":"pipeline","source":"ION Analytics","summary":"GL Capital raises continuation vehicle for China’s SciClone Pharmaceuticals - ION Analytics","headline":"GL Capital raises continuation vehicle for China’s SciClone Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQczctbmxVODgtNFQ2WmlqTnN0T0RzTzdGRVpaTlhZMzVkaTkyVDFXbUJnSXp4dXp2Z19rcm1oNHJXWERlM2FJWDNPR2JlQ2VsOHI3cTl3Qkd3Tl8zMTZ6a19hWXZlbmhHZGZSeGtzUGd3WmpNLTh4LWVodTlwc2NrMEtEQUJmTk9ZaXdtc2ltcjJpS0JrWnRSNGp0VXlDV0Q2VS1SWjdYMlkzaTYteGlF?oc=5","date":"2025-02-28","type":"deal","source":"Contract Pharma","summary":"Eisai Licenses Tasurgratinib to SciClone in Greater China Region - Contract Pharma","headline":"Eisai Licenses Tasurgratinib to SciClone in Greater China Region","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxQa0pHczROVmZBbnd5SGx5b3lDVXdETHF1NjhKOHlEd0hVYmhyb3M0aUMwTkhPTVBZai1jdXlkY2tJTXF3OHlYbjFRU3VwTVJTU2k3b2NDSzNwOGlNZEVnQTRfcjcyMW9PSXJXUTF2aDZINU0yVmx5clcyNnFPUG1VRzUwR05aLVRYdFpxUU42NVhhLVFUcGg4SW5zUTVISlpKZlUwendwcjlkRmRJOFFZRFRzbXE0cno3b2dpMy12UXNPWmgwcUNzQklmd052OV9tTGlIdkVkYi1lYzhXVDduYmVYa25vYUxUWjBibkxJM2NpZmhYNTVN?oc=5","date":"2025-02-28","type":"pipeline","source":"BioSpectrum Asia","summary":"Eisai grants exclusive development and distribution rights for Tasurgratinib in Greater China to SciClone Pharma - BioSpectrum Asia","headline":"Eisai grants exclusive development and distribution rights for Tasurgratinib in Greater China to SciClone Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxQUXFKVDRhU0VfSWd6UlBScTdvWkxQVldqQXB3UDgtdDVCM0hnUVJjSlR0Vmg1Mm9ycGwxMzQ5dmJXOWQtNDFwX2FIV1hIMlRrRkR5NHZidEZTMmtiNnJTTDhRb1FQQVgzc2ZtOTBYR3Q5cE5ULV81NTQwbzEzSXU4dVF5dmotV3B0X3hVenpWa3hhSmRNLUUyS2pibFE0OFpmWVViOWRBWVlXekZnR0lvaHNIVEhERnF4MFlhOE41ckcycVptekI3WWI3WkhQdnk1RFNZczhjQXd0T1JvOXd2NU1yanZzVjQ0dzF0bQ?oc=5","date":"2024-02-27","type":"pipeline","source":"CRISPR Medicine News","summary":"Press Release Service: Sepsis Drug Pipeline Research Report 2024: Insights from 30 Companies and 35 Pipeline Drugs - ResearchAndMarkets.com - CRISPR Medicine News","headline":"Press Release Service: Sepsis Drug Pipeline Research Report 2024: Insights from 30 Companies and 35 Pipeline Drugs - Res","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxONVJIWk0ydEc5WW9lRkpMeUJocGE4cWZ0R0JIVjRQbDN6Qkl0RDZuSDMzTzB4WFdQSXk0ckw5bU9ZRl9vcnVKMEc5blN0VHQtX2p3Tmx1UElOanNUdjkwbm9PRjhrb3QwSkkwYUhKbnlzQlpnQnFVV2UxS2VjRlVpSDBNZGtzM2YxYUN1UGNTQzZVVTZyTTl4Tmxuc0Zla01XTWRKX0VFUlk?oc=5","date":"2021-02-22","type":"pipeline","source":"The Standard (HK)","summary":"Shanghai pharma company thrives on leading treatment - The Standard (HK)","headline":"Shanghai pharma company thrives on leading treatment - The Standard (HK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxPSFhNRXVNeGQ4OGxMa29qWW8tNmJITHNQY2dQRm1iRzhiZVZ3S1h3OEwzaU8wX0psc3V0cncxODY2MFNTOXliUVpteF95X2wzMi1NQlNOYk10empSS1VUbS0yWTRfeUhKSGtaQWNtQk43OEp2Z2d5MzZJTVZpSWhqSFFaQjVNbnh1ZXlQZUdtTmlvREZCZzNrY1dQc09jR1ZHNWUtSk1JWUpFZ2Q4NF9jdlZhYk9tQzZQcEZlX0Z5aUV0WlZLOGZub3NCeEtKTVc4WHNWcUtWSEJTb1NfcVNPUjh0VVZtcm04WVlqUFduS191eGhPTWl1QzdnTHZsQzYtYkI4T3g3bGpTb2c?oc=5","date":"2020-03-19","type":"pipeline","source":"Business Wire","summary":"Tarveda Therapeutics and SciClone Pharmaceuticals International Establish Licensing Agreement for PEN-866 in Greater China - Business Wire","headline":"Tarveda Therapeutics and SciClone Pharmaceuticals International Establish Licensing Agreement for PEN-866 in Greater Chi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOMDZ0aW5YZTdPWnd6ZG5HQTRWV1lva3JucElIYzVDVlBQU2dyRFlCTkZ4aEx0OHk5a29PTDN0cVUydXlqZHhpOC1aVU1RaGtaR1ZLSlpxTHB0bkUwUjVJV0U5dDZNb3l4YXlHQ0pJcGFUVkZ5NzZPVkViSVRGLXA3TzFGd0VGMnk3VDk4?oc=5","date":"2018-05-31","type":"pipeline","source":"pharmaphorum","summary":"How AI and blockchain can reduce corruption in Big Pharma - pharmaphorum","headline":"How AI and blockchain can reduce corruption in Big Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxOdmJiSTZmb0otTTRWZjZCbXZrYjVKTVFsWTN2LWktay1xaXlTM2VsaFNxdGZNVzlaV3RJYlpPZENIRFdXZW9ZUE05MF9qS2FQT1pJU0M0OXpqZVk2VHJWM3pyTDNQWHJlR3U2cF85MkxoUnRmVHZTM1BucU53MEgzOC1aVFNEeDhvc0kxZzh5anBDRElkVzhWb0thdjJNRGdqTEU5MnNMTGl1X0FIWmdiVnBKNWxsQTdIQXJLcnJBalpHamlucXdYaWRDcllSemJPUEpJS2loOFdvT1pEdzFFTmRfTjBvZw?oc=5","date":"2017-06-08","type":"deal","source":"PR Newswire","summary":"SciClone Enters Into Definitive Merger Agreement To Be Acquired By Consortium Led By GL Capital - PR Newswire","headline":"SciClone Enters Into Definitive Merger Agreement To Be Acquired By Consortium Led By GL Capital","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQTVAwUHFndHhVVllDekUyWGxxMWpXdE04MVNEVTUzaE05UlpWVkFoeklfOW95Rmw5VjBLZUxJZzRUVDk4ZGdGLW9nQlR4QmZUUEdZWjFubERtcUVTWjg3VW5DRUVKVlhPdnR6QXpBXzVYRTBEd3NqbHdwS19jNTJxR3ZJeWVTMXZyLXhhOXNxSUVuci1zT2M3RkZ3?oc=5","date":"2016-02-23","type":"pipeline","source":"Forbes","summary":"Why Pharma Faces So Many Corruption Allegations - Forbes","headline":"Why Pharma Faces So Many Corruption Allegations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPLVFqVTV5R3g3VjNqQ0ZvLXU1YXVERFFoQ3ZSNlI0TDA5ZUJKRXZ6Qml1NjlhNnUzdEh6M0lDQnNXYkVxR0JGQll5Qi1YVzBtcmhDV3FoeDJRWlhyVEZ4VUduZG5oWGdSNDJFYmJYa29QeGM2ZXprQkI0ZWR2VFhieFNra2JSNzlUTndmNA?oc=5","date":"2011-04-19","type":"deal","source":"Asian Scientist Magazine","summary":"SciClone Buys NovaMed In China Expansion - Asian Scientist Magazine","headline":"SciClone Buys NovaMed In China Expansion","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":160096000,"revenuePeriod":"2016-12-31","revenueHistory":[{"value":160096000,"period":"2016-12-31"},{"value":157257000,"period":"2015-12-31"},{"value":157257000,"period":"2015-12-31"},{"value":134790000,"period":"2014-12-31"},{"value":134790000,"period":"2014-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":30729000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":241898000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}